Analyst Price Targets — OPK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 30, 2025 8:10 pm | — | Jefferies | $1.60 | $1.46 | TheFly | Opko Health downgraded to Hold from Buy at Jefferies |
| September 17, 2024 6:52 am | Yi Chen | H.C. Wainwright | $3.00 | $1.70 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK) |
| December 15, 2022 6:56 am | — | H.C. Wainwright | $3.00 | $1.29 | Benzinga | HC Wainwright & Co. Initiates Coverage On OPKO Health with Buy Rating, Announces Price Target of $3 |
| August 4, 2022 8:38 pm | Edward Tenthoff | Piper Sandler | $4.00 | $2.40 | TheFly | Opko Health price target lowered to $4 from $5 at Piper Sandler |
Latest News for OPK
Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in the undefined quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 shares of the biotechnology company's stock, valued at approximately $618,000. Connor Clark and Lunn Investment Management
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OPK.
U.S. House Trading
No House trades found for OPK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.